Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188488 | 0.81 | ALDH1A1 (0.46) | PIK3CAMTOR | |
| SCHEMBL1899134 | 0.81 | PIK3CA (0.61) | PIK3CAMTOR | |
| SCHEMBL1983390 | 0.79 | PIK3CA (0.78) | PIK3CAMTOR | |
| SCHEMBL1982110 | 0.78 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL3329395 | 0.78 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL2006204 | 0.77 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL6128255 | 0.76 | PIK3CA (0.57) | PIK3CAMTOR | |
| SCHEMBL1900964 | 0.76 | MTOR (0.69) | PIK3CAMTOR | |
| SCHEMBL188507 | 0.76 | PIK3CA (0.63) | PIK3CAMTOR | |
| SCHEMBL1987460 | 0.76 | PIK3CA (1.00) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012149308-A1 | METHOD OF TREATING LYMPHOMA USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR | EXELIXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011100319-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K AND MTOR IN COMBINATION WITH AUTOPHAGY INHIBITORS | EXELIXIS, INC. (US) | 2011-08-18 | — | — | WO | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |